History of Value Creation

1920 - 1955

Took our first step as a pharmaceutical company

In 1920, Yasohachi Yamaguchi established Teikoku Hormone

manufacture and sales of hormone preparations based on the

unique idea of creating useful medicines from animal organs.

THYRADIN

Six-month settlement period

(Two six-month periods were combined

Although the company experienced hardships such as the Great Kanto Earthquake, and the loss of its head office and factory during the Second World War, it was rebuilt under a new organizational structure, and listed its shares on the

Tokyo Stock Exchange in 1955.

Research Institute. It began the research, development,

Since our founding in 1920 as a pioneer in hormone preparations, we have unerringly continued on our journey, while always keeping in mind our essential mission as a company that is directly linked to life and health. In 2021, we transitioned to a holding company structure, and took a new step toward the next 100 years. We will continue to respond to the changing times and environment, and contribute to society as we evolve into a total healthcare company.

1945

Women's suffrage

in Japan

Eight-month

settlement period

1955 - 2005

wide-ranging contributions to society

After the postwar reconstruction period, the company worked to modernize its management through organizational reforms, expansion of its sales and production systems, reorganization of its research functions, and reinforcement of its advertising activities. In addition to entering the field of veterinary pharmaceuticals, the company also strived to diversify its business and worked toward corporate growth in the midst of an era of rapid economic growth.





Became a company that makes





Aim for further growth

2021 -

ASKA Pharmaceutical Holdings' Medium-Term Management Plan 2025 was launched in 2021. In conjunction with the shift to a holding company structure, the Company not only aims to build a flexible organization that is capable of swift decision-making, but also to achieve further sustainable growth for the entire Group by further strengthening its governance structure.

FY2022

2022

Enforcement of Revised Act on the Promotion

of Women's Active

Engagement in

Professional Life

¥60,461 million



2005 - 2021

for generic drugs that meet the needs of the times.

Formation of ASKA Pharmaceutical Co., Ltd.

In 2005, ASKA Pharmaceutical Co., Ltd. was established to develop and market new drugs, specializing in the three priority areas of internal

medicine, obstetrics and gynecology (Ob/Gyn), and urology with the

aim of becoming a competitive specialty pharma company. The company took on challenges for the next stage, such as strengthening efforts

LUTEUM

1986

Enforcement of

Equal Employment

Opportunity Act

1975 International Women's Year

12,409

REWELL "ASKA

24,390

1992

Enforcement of







23,537

45,849





Enforcement of Act on the Promotion of Women's Active Engagement in Professional Life





(Merged with Grelan Pharmaceutical Co., Ltd. in October 2005)





ASKA HD REPORT 2023 7

2020



for the data for years 1930-1937) Four-month settlement period settlement period ASKA HD REPORT 2023